Gene-carried hepatoma targeting complex induced high gene transfection efficiency with low toxicity and significant antitumor activity

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 3191-3202

  Zhao, Qing Qing ^a,b   Hu, Yu Lan ^a   Zhou, Yang ^c   Li, Ni ^a   Han, Min ^a   Tang, Gu Ping ^a   Qiu, Feng ^b   Tabata, Yasuhiko ^d   Gao, Jian Qing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^c IOWA STATE UNIVERSITY   (United States)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Antitumor; Chitosan; Peptide; Polyethylenimine; Targeting

Indexed keywords

CHITOSAN; INTERLEUKIN 12; LUCIFERASE; PHENYLALANYLGLUTAMYLHISTIDYLPROLYLSERYLPHENYLALANINE; POLYETHYLENEIMINE; POLYPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CHEMICAL COMPOSITION; COMPETITIVE INHIBITION; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DNA VECTOR; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ASSAY; FEMALE; GENE DELIVERY SYSTEM; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIVER CELL CARCINOMA; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; ULTRAVIOLET SPECTROPHOTOMETRY; ZETA POTENTIAL;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; CHITOSAN; DNA; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; GENETIC VECTORS; HUMANS; INTERLEUKIN-12; LIVER NEOPLASMS; MICE; MICE, INBRED ICR; OLIGOPEPTIDES; PARTICLE SIZE; POLYETHYLENEIMINE; SURVIVAL ANALYSIS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84870328242     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S30909     Document Type: Article

References (29)

1. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, etal. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669-672.
2. Boyd AC. Gene and stem cell therapy. In: Bush A, Alton EWFW, Davies JC, Griesenbach U, Jaffe A, editors. Cystic Fibrosis in the 21st Century. Basel: Karger; 2006:221-232.
3. Kaplitt MG, Feigin A, Tang C, etal. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007;369(9579): 2097-2105.
4. Yang ZR, Wang HF, Zhao J, etal. Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy. Cancer Gene Ther. 2007;14(7):599-615.
5. Anderson WF. Human gene therapy. Nature. 1998;392(6679):25-30.
6. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov. 2005;4(7): 581-593.
7. Verma IM, Somia N. Gene therapy-promises, problems and prospects. Nature. 1997;389(6648):239-242.
8. Koping-Hoggard M, Varum KM, Issa M, etal. Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers. Gene Ther. 2004;11(19): 1441-1452.
9. Kim TH, Kim SI, Akaike T, Cho CS. Synergistic effect of poly(ethylenimine) on the transfection efficiency of galactosylated chitosan/DNA complexes. J Control Release. 2005;105(3):354-366.
10. Densmore CL, Orson FM, Xu B, etal. Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization. Mol Ther. 2000;1(2):180-188.
11. Kichler A, Leborgne C, Danos O. Dilution of reporter gene with stuffer DNA does not alter the transfection efficiency of polyethylenimines. J Gene Med. 2005;7(11):1459-1467.
12. Fischer D, Bieber T, Li Y, Elsasser HP, Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res. 1999;16(8):1273-1279.
13. Kunath K, von Harpe A, Fischer D, Kissel T. Galactose-PEI-DNA complexes for targeted gene delivery: degree of substitution affects complex size and transfection efficiency. J Control Release. 2003;88(1): 159-172.
14. Gao JQ, Zhao QQ, Lv TF, etal. Gene-carried chitosan-linked-PEI induced high gene transfection efficiency with low toxicity and significant tumor-suppressive activity. Int J Pharm. 2010;387(1-2):286-294.
15. Zhao QQ, Chen JL, Lv TF, etal. N/P ratio significantly influences the transfection efficiency and cytotoxicity of a polyethylenimine/chitosan/DNA complex. Biol Pharm Bull. 2009;32(4):706-710.
16. Park IK, Park YH, Shin BA, etal. Galactosylated chitosan-graft-dextran as hepatocyte-targeting DNA carrier. J Control Release. 2000;69(1): 97-108.
17. Park MR, Kim HW, Hwang CS, etal. Highly efficient gene transfer with degradable poly(ester amine) based on poly(ethylene glycol) diacrylate and polyethylenimine in vitro and in vivo. J Gene Med. 2008;10(2): 198-207.
18. Zhang C, Gao S, Jiang W, etal. Targeted minicircle DNA delivery using folate-poly(ethylene glycol)-polyethylenimine as non-viral carrier. Biomaterials. 2010;31(23):6075-6086.
19. Bonoiu AC, Mahajan SD, Ding H, etal. Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc Natl Acad Sci U S A. 2009;106(14):5546-5550.
20. Zhang B, Zhang Y, Wang J, etal. Screening and identification of a targeting peptide to hepatocarcinoma from a phage display peptide library. Mol Med. 2007;13(5-6):246-254.
21. Farhood H, Bottega R, Epand RM, Huang L. Effect of cationic cholesterol derivatives on gene transfer and protein kinase C activity. Biochim Biophys Acta. 1992;1111(2):239-246.
22. Kopatz I, Remy JS, Behr JP. A model for non-viral gene delivery: through syndecan adhesion molecules and powered by actin. J Gene Med. 2004;6(7):769-776.
23. Feng M, Lee D, Li P. Intracellular uptake and release of poly(ethyleneimine)-co-poly(methyl methacrylate) nanoparticle/pDNA complexes for gene delivery. Int J Pharm. 2006;311(1-2): 209-214.
24. Hashimoto M, Morimoto M, Saimoto H, Shigemasa Y, Sato T. Lactosylated chitosan for DNA delivery into hepatocytes: the effect of lactosylation on the physicochemical properties and intracellular trafficking of pDNA/chitosan complexes. Bioconjug Chem. 2006;17(2): 309-316.
25. Colombo MP, Trinchieri G. Interleukin-12in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13(2):155-168.
26. Manetti R, Parronchi P, Giudizi MG, etal. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med. 1993;177(4):1199-1204.
27. Manetti R, Gerosa F, Giudizi MG, etal. Interleukin 12induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med. 1994;179(4): 1273-1283.
28. Del Vecchio M, Bajetta E, Canova S, etal. Interleukin-12: biological properties and clinical application. Clin Cancer Res. 2007;13(16): 4677-4685.
29. Berraondo P, Prieto J, Gonzalez-Aseguinolaza G. Advances in interleukin-12gene therapy for acquired liver diseases. Curr Gene Ther. 2009;9(2):62-71.